ClinicalTrials.gov
public full text
Public Domain
Phase III Study of ASP2151 in Herpes Zoster Patients
To evaluate the efficacy and safety of ASP2151 (200 mg and 400 mg) in comparison with valaciclovir (VACV) 3000 mg in patients with herpes zoster.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Reduction of Postherpetic Neuralgia in Herpes Zoster#829874
- Rhomboid Intercostal and Subserratus Plane Block Versus Paravertebral Block for Thoracic Herpes Zoster#850507
- Efficacy of Electroacupuncture for Acute Herpes Zoster-Associated Pain and Biomarker Evaluation#1075372
- Efficacy of valaciclovir in preventing herpes zoster in patients receiving anifrolumab#156363
- The Efficacy of Systemic Valacyclovir (Valtrex) on Periodontitis#915199
Record · ID 850870
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive